The OPERA trial randomized 60 people with stages 3–5 non-dialysis CKD and left ventricular hypertrophy to paricalcitol 1–2 μg daily (depending on serum PTH) or matching placebo [29]. The gene discussed is PTH; the disease is chronic kidney disease.